AZELEX
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- AZELEX
- Generic name
- AZELAIC ACID
- Manufacturer
- Almirall, LLC
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- ebdfcaf7-b5d6-47e1-be87-ccaba4b97e75
- SPL ID
- ae821f0c-ec53-4612-a505-e1aa9d73a158
- Version
- 6
- Effective date
- 2024-03-04
- Source export date
- 2026-09-28
- Source partition
- 5
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0005-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-09-28/9839785a692b692224cd5f90f9e3a9514c9923a6f521ab83eed3bedc7c0e1d05/drug-label-0005-of-0014.json.zip
- Source manifest SHA-256
- cd2e66336a5cd2223fa3995098fdbdb84c6a7ee5c0a4addb236ccb22dd1e6887
- Import run
- 20260929T050834Z
- Imported at
- 2026-09-29 05:31:57
| Harmonized routes |
|---|
| CUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 020428 | derived:openfda.application_number |
| application number | NDA020428 | openfda.application_number | |
| brand name | AZELEX | openfda.brand_name | |
| generic name | AZELAIC ACID | openfda.generic_name | |
| manufacturer name | Almirall, LLC | openfda.manufacturer_name | |
| ndc | package | 16110-869-50 | openfda.package_ndc |
| ndc | package | 16110-869-30 | openfda.package_ndc |
| ndc | product | 16110-869 | openfda.product_ndc |
| ndc11 | package | 16110086950 | derived:openfda.package_ndc |
| ndc11 | package | 16110086930 | derived:openfda.package_ndc |
| rxcui | 1043753 | openfda.rxcui | |
| rxcui | 1041520 | openfda.rxcui | |
| spl id | ae821f0c-ec53-4612-a505-e1aa9d73a158 | id | |
| spl set id | ebdfcaf7-b5d6-47e1-be87-ccaba4b97e75 | set_id | |
| unii | F2VW3D43YT | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNINGS AZELEX ® cream is for dermatologic use only and not for ophthalmic use. There have been isolated reports of hypopigmentation after use of azelaic acid. Since azelaic acid has not been well studied in patients with dark complexions, these patients should be monitored for early signs of hypopigmentation.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
ADVERSE REACTIONS During U.S. clinical trials with AZELEX ® cream, adverse reactions were generally mild and transient in nature. The most common adverse reactions occurring in approximately 1-5% of patients were pruritus, burning, stinging and tingling. Other adverse reactions such as erythema, dryness, rash, peeling, irritation, dermatitis, and contact dermatitis were reported in less than 1% of subjects. There is the potential for experiencing allergic reactions with use of AZELEX ® cream. In patients using azelaic acid formulations, the following additional adverse experiences have been reported rarely: worsening of asthma, vitiligo depigmentation, small depigmented spots, hypertrichosis, reddening (signs of keratosis pilaris), and exacerbation of recurrent herpes labialis.
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.